- Clinical Technology
- Adult Immunization
- Hepatology
- Pediatric Immunization
- Screening
- Psychiatry
- Allergy
- Women's Health
- Cardiology
- Pediatrics
- Dermatology
- Endocrinology
- Pain Management
- Gastroenterology
- Infectious Disease
- Obesity Medicine
- Rheumatology
- Nephrology
- Neurology
- Pulmonology
8 Questions on the Medical News
Everything from Obamacare to end-of-life care has made the news in recent days. This quick quiz will test your knowledge of the latest developments.
Everything from Obamacare to end-of-life care has made the medical news in recent days. Take this quick quiz to test your knowledge of the latest developments.
Note: If you would like more information on any of the questions, links to the original articles, “Obamacare Special Report and More Medical News” and” An App for Aspirin and Other Medicine in the News,” are provided on the last page of the quiz.
Question 1:
Answer and Question #2 on Next Page »
The correct answer is D. US president Barack Obama
Question 2.
Answer and Question #3 on Next Page »
The correct answer is A. True
Question 3.
Answer and Question #4 on Next Page »
The correct answer is D. Associated weakly with all-cause mortality, not significantly with CVD, and inversely with diabetes
Question 4.
Answer and Question #5 on Next Page »
The correct answer is B. False
Question 5.
Answer and Question #6 on Next Page »
The correct answer is C. 40%
Question 6.
Answer and Question #7 on Next Page »
The correct answer is B. Significantly better for patients with cancer than for those with end-stage renal disease
Question 7.
Answer and Question #8 on Next Page »
The correct answer is A. Naloxone
Question 8.
Answer on Next Page »
The correct answer is B. Decelerated substantially
For more information on all questions and answers, please visit “Obamacare Special Report and More Medical News” and “An App for Aspirin and Other Medicine in the News.”
Roche, Alnylam Advance Zilebesiran Into Phase 3 CV Outcomes Trial for Resistant Hypertension
September 9th 2025Zilebesiran’s twice-yearly dosing and sustained BP reductions could offer a new therapeutic approach for adults with resistant hypertension and high CV risk who are uncontrolled on current SOC regimens.
Oral PCSK9 Inhibitor Enlicitide Meets All End Points in Phase 3 Hypercholesterolemia Trial
September 2nd 2025At week 24, patients receiving once-daily enlicitide demonstrated statistically significant and clinically meaningful reductions in low-density lipoprotein cholesterol compared with placebo.
